AptaBio Therapeutics Inc.

A293780

KR7293780003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
5,650 ^KRW	-2.42%		-2.25%	-37.57%

2023	AptaBio Therapeutics Inc. announced that it has received KRW 49.999966652 billion in funding	CI
2023	AptaBio Therapeutics Inc. announced that it expects to receive KRW 49.999966652 billion in funding	CI

AptaBio Therapeutics Inc.(KOSDAQ:A293780) added to S&P Global BMI Index

December 23, 2019 at 12:00 am EST

Latest news about AptaBio Therapeutics Inc.

AptaBio Therapeutics Inc. announced that it has received KRW 49.999966652 billion in funding	23-08-23	CI
AptaBio Therapeutics Inc. announced that it expects to receive KRW 49.999966652 billion in funding	23-08-15	CI
AptaBio Therapeutics Inc.(KOSDAQ:A293780) added to S&P Global BMI Index	19-12-23	CI
AptaBio Therapeutics Inc.(KOSDAQ:A293780) added to S&P Global BMI Index	19-12-23	CI
AptaBio Therapeutics Inc. has completed an IPO in the amount of KRW 65.4 billion.	19-06-10	CI
AptaBio Therapeutics Inc. has filed an IPO.	18-12-14	CI
Hope Biosciences Signs Licensing Agreement with Aptabio Therapeutics	17-01-22	CI

Chart AptaBio Therapeutics Inc.

Duration

Period

More charts

Aptabio Therapeutics Inc. is a Korea-based company that researches and develops new drugs. The Company is developing anti-cancer drugs, drugs for inflammatory and fibrotic diseases and diabetic complications drugs, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APTABIO THERAPEUTICS INC.	-37.57%	91.53M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B